Board Member
Yarrow Bioscience, Inc. (YARW)Equibles does not estimate personal net worth.
Get an email with a short summary when Yarrow Bioscience, Inc. publishes a filing, an earnings call transcript or a press release.
Get YARW alertsDavid Domzalski is recorded as Board Member at Yarrow Bioscience, Inc. (YARW) since January 1, 2020. The newest filing on record that lists David Domzalski as Board Member at Yarrow Bioscience, Inc. (YARW) is dated November 12, 2025. Yarrow Bioscience, Inc. reported in an 8-K filed July 28, 2026 that David Domzalski resigned as President and Chief Executive Officer, effective July 27, 2026. Yarrow Bioscience, Inc. reported in an 8-K filed December 12, 2024 that David Domzalski was appointed Class III director, effective December 12, 2024. The proxy statement of Yarrow Bioscience, Inc. reports total compensation of $1,973,607 for David Domzalski in fiscal 2024, including a base salary of $637,560. Disclosed compensation is on record for 6 fiscal years. David Domzalski has spoken on 6 earnings calls and 2 other investor events across 1 company, most recently for Yarrow Bioscience, Inc. on July 9, 2025. Yarrow Bioscience, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Yarrow Bioscience, Inc. includes Rebecca Frey (CEO and Board Member), Bill Lundberg (Chairman and Board Member), Andrew Saik (CFO) and 7 others.
“each of David Domzalski, VYNE's President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE's Chief Scientific Officer, and Mutya Harsch, VYNE's Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026”
“The election of two nominees to serve as Class III directors to hold office until the 2027 annual meeting of stockholders and until their respective successors are elected.”
“As we announced in our press release this morning, Vine and Yarrow Bioscience have entered into a merger agreement pursuant to which the companies will combine in an all-stock transaction.”
“As we announced in our press release this morning, Vine and Yarrow Bioscience have entered into a merger agreement pursuant to which the companies will combine in an all-stock transaction.”
“On our previous earnings call, we announced our transformational decision to refocus our efforts toward developing new and innovative therapies for the treatment of immuno-inflammatory diseases.”
“Hopefully, you had a chance to read the two press releases that we issued this morning related to our second quarter earnings and announcing our new license agreement with In4Derm.”
“I’d like to talk about our recent progress and plans for 2021. As we continue to build the business, we are focused on three key areas. The first is commercial execution, where our top priority is to expand initial trials of AMZEEQ and ZILXI and grow continued utilization of our products.”
2020-01-01–present
Last confirmed November 12, 2025
Start not stated–2026-07-27
Biotechnology · Healthcare
Board Member
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Yarrow Bioscience, Inc. (YARW) | President and Chief Executive Officer | $637,560 | $1,973,607 |
| 2023 | Yarrow Bioscience, Inc. (YARW) | President and Chief Executive Officer | $637,560 | $2,716,350 |
| 2022 | Yarrow Bioscience, Inc. (YARW) | President and Chief Executive Officer | $637,560 | $1,293,464 |
| 2021 | Yarrow Bioscience, Inc. (YARW) | President and Chief Executive Officer | $637,560 | $4,852,925 |
| 2020 | Yarrow Bioscience, Inc. (YARW) | President and Chief Executive Officer | $500,500 | $2,872,008 |
| 2019 | Yarrow Bioscience, Inc. (YARW) | President and Chief Executive Officer | — | — |
